CHENGDU, China and SEATTLE
and IRVINE, Calif., March 28, 2019 /PRNewswire/ -- Biokin
Pharmaceutical Co. Ltd., ("Biokin Pharma") a leading pharmaceutical
company with operations in China
and U.S., and Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW)
("Cryoport"), the world's leading temperature-controlled logistics
company dedicated to the life sciences industry, today announced
Cryoport's full suite of temperature-controlled solutions will
support Biokin Pharma's pending Phase I and II clinical trials in
immuno-oncology in both the U.S. and China.
Biokin Pharma, is a biopharmaceutical company based in
China focused on the treatment of
cancer through developing novel therapeutic antibodies and
antibody-drug conjugates ("ADC"s). Led by a group of highly
experienced immuno-oncology scientists, the company utilizes
several technology platforms to develop world class advanced
antibody-based drug therapies. Its wholly-owned subsidiary
SystImmune Inc. ("SystImmune"), which is funded in part by OrbiMed,
was formed to advance its mission in the
United States. Partnering with Cryoport will enable Biokin
Pharma and SystImmune to utilize Cryoport's full range of
temperature-controlled logistics solutions to support its drug
manufacturing processes across the globe. These solutions include
the Cryoport Express® shippers, the industry-leading Cryoportal™
Logistics Management Platform, Smartpak II™ Condition Monitoring
System and 24/7/365 logistics support.
"We are pleased to choose the highly reliable condition- and
time-sensitive logistics solutions provided by Cryoport to support
our upcoming clinical studies using Bispecific and Multi-specific
Antibody, ADC, and T-cell Therapy," said Dr. Yi Zhu, Chairman of Biokin Pharma and its U.S.
subsidiary, Systimmune of Seattle,
WA. "By relying on Cryoport's excellent solutions, Biokin
Pharma and Systimmune will continue to have the best possible
viability and recovery of critical cells, vectors, antibodies and
other materials, even after time-consuming international or
domestic transportation, to ensure the best outcome for our
patients."
"As the regenerative medicine market rapidly matures, the demand
for our technology-driven solutions to support trials across the
globe is growing. We look forward to working alongside Biokin
Pharma and its U.S. subsidiary to ensure reliable, secure logistics
support for their temperature-sensitive commodities as they advance
the development of potentially life-saving therapies," said
Mark Sawicki, PhD, Chief Commercial
Officer of Cryoport.
About Biokin Pharma
Biokin Pharma researches and develops innovative therapies in
immuno-oncology for cancer patients worldwide using targeted
antibody, ADC, and cell therapy. For 2019 to 2020, Biokin
expects to start four clinical trials in the U.S. and China using its SI-B001, SI-B003/032,
GNC-038/039 therapies. One of the industry's leading biopharma
companies, Biokin Pharma was founded in 1996 by Dr. Yi Zhu with GMP R&D and manufacturing
facilities in China and a US
subsidiary- Systimmune Inc in Seattle WA. Biokin and
Systimmune today have a leading portfolio of medicines targeting
Epithelial Tumor, Non-small cell lung cancer, blood cancer, solid
tumor, and other indications.
For more information, visit http://www.baili-pharm.com or
http://www.systimmune.com.
About Cryoport, Inc.
Cryoport is the life sciences industry's most trusted global
provider of temperature-controlled logistics solutions for
temperature-sensitive life sciences commodities, serving the
biopharmaceutical market with leading-edge logistics solutions for
biologic materials, such as regenerative medicine, including
immunotherapies, stem cells and CAR T-cells. Cryoport's solutions
are used by points-of-care, CRO's, central laboratories,
pharmaceutical companies, manufacturers, university researchers et
al; as well as the reproductive medicine market, primarily in IVF
and surrogacy; and the animal health market, primarily in the areas
of vaccines and reproduction. Cryoport's proprietary Cryoport
Express® Shippers, Cryoportal® Logistics Management Platform,
leading-edge SmartPak II™ Condition Monitoring System and
geo-sensing technology, paired with unparalleled cold chain
logistics expertise and 24/7 client support, make Cryoport the
end-to-end cold chain logistics partner that the industry trusts.
Cryoport is dedicated to: simplifying global cold chain logistics
through innovative technology, unmatched monitoring and data
capture and support, including consulting; delivering the most
advanced temperature-controlled logistics solutions for the life
sciences industry; and providing vital information that provides
peace of mind throughout the life of each logistics process.
For more information, visit www.cryoport.com. Sign up to
follow @cryoport on
Twitter at www.twitter.com/cryoport.
Forward Looking Statements
Statements in this news release which are not purely historical,
including statements regarding Cryoport, Inc.'s intentions, hopes,
beliefs, expectations, representations, projections, plans or
predictions of the future are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. It
is important to note that the Company's actual results could differ
materially from those in any such forward-looking statements.
Factors that could cause actual results to differ materially
include, but are not limited to, risks and uncertainties associated
with the effect of changing economic conditions, trends in the
products markets, variations in the Company's cash flow, market
acceptance risks, and technical development risks. The Company's
business could be affected by a number of other factors, including
the risk factors listed from time to time in the Company's SEC
reports including, but not limited to, the Company's 10-K for the
year ended December 31, 2018 filed
with the SEC. The Company cautions investors not to place undue
reliance on the forward-looking statements contained in this press
release. Cryoport, Inc. disclaims any obligation, and does not
undertake to update or revise any forward-looking statements in
this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biokin-pharmaceutical-selects-cryoports-temperature-controlled-solutions-for-its-pending-phase-i-and-phase-ii-trials-300820262.html
SOURCE Cryoport, Inc.